InsiderTrades

Form 4 for RNAC Cartesian Therapeutics, Inc.

Accepted 2022-09-06 00:00:00 ET · period of report 2022-09-01 · accession 0001453687-22-000129 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-09-06 2022-09-01 RNAC Brunn Carsten Pres, CEO, Dir M - OptEx $0.00 +10.9K 545.3K +2% $0
D 2022-09-06 2022-09-02 RNAC Brunn Carsten Pres, CEO, Dir S - Sale+OE $1.85 -4,768 540.6K -0.9% -$8,821
D 2022-09-06 2022-09-01 RNAC Brunn Carsten Pres, CEO, Dir M - OptEx $0.00 -10.9K 10.9K -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-09-01 M A 10,937 $0.00 545,327 D — —
2 Common Common Stock 2022-09-02 S D 4,768 $1.85 540,559 D — — (F2) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.825 to $1.855. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3 Derivative Restricted Stock Units 2022-09-01 M D 10,937 $0.00 10,938 D — · — to — 10,937 Common Stock (F3) Each restricted stock unit represents a contingent right to receive one share of common stock. (F4) This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date.